GENFFGenflow Biosciences Plc

About Genflow Biosciences Plc (GENFF)

Genflow Biosciences Plc (GENFF) is a Biotechnology company headquartered in London, ENG, United Kingdom whose shares trade over-the-counter on the OTCQB tier.

Genflow Biosciences is dedicated to the development and commercialization of novel therapeutics targeting ageing in dogs and humans.

Products and services

The Company is a preclinical biotechnology company focused on the development of innovative biological interventions (namely gene therapies) which are aimed at tackling the effects of ageing, potentially slowing or halting the ageing process and so reducing the incidence of age-related diseases and thereby increasing health span. The Company is seeking to develop treatments that can be applied to both humans and dogs.

GENFF key facts

Ticker symbol

GENFF

Market tier

OTCQB

Sector

Healthcare

Industry

Biotechnology

Headquarters

London, ENG, United Kingdom

Country of incorporation

GB

Year of incorporation

2021

Employees

1

Estimated market cap

$5.49M (as of May 6, 2025)

Shares outstanding

349,706,618

Reporting standard

International Reporting: LSE - London Stock Exchange

Audit status

Audited

Fiscal year end

12/31

Latest filing

Annual Report (Dec 31, 2024)

Genflow Biosciences Plc leadership

• Eric J Leire — CEO
• Jonathan Paterson — IR
• Emily Bavin — Company Secretary
• Nicola Baldwin — Company Secretary

Explore more: Biotechnology stocks · Healthcare sector · OTCQB stocks · OTC stocks starting with G